Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Part of paid clinical trials in Columbus, Ohio.

Sponsor
Ohio State University Comprehensive Cancer Center
Study ID
NCT00267696
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
  • Gemcitabine — DRUG
    A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
  • Carboplatin — DRUG

Study Details

The purpose of this study is to test the effectiveness, safety and tolerability of the drug combination: gemcitabine, carboplatin and bevacizumab in patients that have been diagnosed with platinum sensitive recurrent ovarian cancer, fallopian tube or primary peritoneal cancer.

Key Dates

First listed
Dec 21, 2005
Start date
Nov 30, 2005
Status verified
Apr 2015
Primary completion
Sep 30, 2013
Completion
Dec 31, 2013

Study Design

Enrollment
45 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Gemcitabine/carboplatin/bevacizumab
    A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.

Primary Outcome Measure

Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or Responding. [ Time Frame: up to 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Ohio State University & James Cancer HospitalColumbusOhio43210-

Find similar trials in Columbus, OH

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
The Ohio State University & James Cancer Hospital· Columbus, OH

Related Studies